Programa de trasplantes de riñón

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. A Study of Kidney Transplant Recipients: Development of a Database for a Multicenter Consortium

   Rochester, Minn.

   The purpose of this study is to collect and share detailed clinical data from all kidney transplant recipients from 7 kidney transplant centers (Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Jacksonville, FL; Cornell University, New York, NY; University of Michigan, Ann Arbor, MI; Henry Ford, Detroit, MI; University of Pittsburgh Medical Center, Pittsburg, PA) to retrospectively and prospectively study kidney transplant recipients.

2. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

   Rochester, Minn.

   The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE.

3. A Study to Evaluate the Safety of the SARS-CoV-2 Vaccination in Patients Waitlisted for Solid Organ Transplantation

   Jacksonville, Fla.

   The purpose of this study is to determine the safety of the SARS-CoV-2 vaccination in patients listed for solid organ transplantation, including heart, lung, liver, kidney, and pancreas.

    

4. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.